Question 1

What is the focus of OncoC4?

Accepted Answer

OncoC4 develops first-in-class and best-in-class medicines for hard-to-treat cancers by leveraging CTLA-4, CD24, and siglecs.

Question 2

What is the company's approach to cancer therapies?

Accepted Answer

OncoC4 is poised to make cancer therapies safer, more effective, and more durable by leveraging innate and adaptive immune checkpoints, such as CTLA-4, CD24, and siglecs, to target cancer cells and boost immune response.

Question 3

What is the CTLA-4 program?

Accepted Answer

OncoC4's CTLA-4 program aims to develop a new and enduring generation of CTLA-4 antibody therapy, including the company's candidate Gotistobart, which is currently partnered with BioNTech and is poised to change the treatment of patients with immunotherapy-resistant non-small cell lung cancer and other advanced tumors.

Question 4

What is the company's focus on siglecs?

Accepted Answer

OncoC4 is working to target siglec signaling to unleash cancer immunity and to reduce adverse events associated with immunotherapy, antibody-drug conjugates, and other cancer treatments, as siglecs play a crucial role in mediating the body's immune response.

Question 5

What is the CD24 platform?

Accepted Answer

OncoC4's CD24 platform aims to exploit the critical signaling pathway of CD24, which is overexpressed in 70% of cancers, to treat solid and hematologic malignancies. The company's cancer-specific antibody has the potential to target CD24 on cancer-specific cells, which has eluded science due to its expression in normal tissues.

OncoC4, Inc.

Company Overview

Company Name

Address

Website

Google Reviews

About OncoC4, Inc.

More Companies in Maryland

Frequently Asked Questions about OncoC4, Inc.

What is the focus of OncoC4?

What is the company's approach to cancer therapies?

What is the CTLA-4 program?

What is the company's focus on siglecs?

What is the CD24 platform?

Technologies Used

Social Profiles

Key Decision Makers